DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,703,482 B2 Oshimura Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,703,482 B2 Oshimura Et Al USOO8703482B2 (12) United States Patent (10) Patent No.: US 8,703,482 B2 Oshimura et al. (45) Date of Patent: Apr. 22, 2014 (54) HUMAN ARTIFICIAL CHROMOSOME (HAC) Rasheed et al. “Characterization of a Newly Derived Human Sar VECTOR coma Cell Line (HT-1080).” Cancer, 1974, vol. 33, pp. 1027-1033. R. Moreadith etal, “Gene targeting in embryonic stem cells: the new physiology and metabolism.” J Mol Med, 1997, vol. 75, pp. 208-216. (75) Inventors: Mitsuo Oshimura, Tottori (JP); L. Mullins et al., “Perspective Series: Molecular Medicine in Geneti Motonobu Katoh, Tottori (JP); Kazuma cally Engineered Animals: Transgenesis in the Rat and Larger Ani Tomizuka, Gunma (JP); Yoshimi mals,” Journal of Clinical Investigation, 1996, vol. 97, No. 7, pp. Kuroiwa, Gunma (JP); Minoru 1557-1560. Kakeda, Gunma (JP) M. Pera et al. “Human embryonic stem cells,” Journal of Cell Sci ence, 2000, vol. 113, pp. 5-10. Hattori et al. “The DNA sequence of human chromosome 21.” (73) Assignee: Kyowa Hakko Kirin Co., Ltd., Tokyo Nature, 2000, vol. 405, No. 6784, pp. 311-319. (JP) European Search Report dated May 18, 2006 for counterpart appli cation PCT/JP0312734 to parent U.S. Appl. No. 10/530.207. (*) Notice: Subject to any disclaimer, the term of this Y. Kuroiwa et al. “Efficient modification of a human chromosome by patent is extended or adjusted under 35 telomere-directed truncation in high homologous recombination U.S.C. 154(b) by 176 days. proficient chicken DT40 cells.” Nucleic Acids. Res., 1998, vol. 26, No. 14, pp. 3447-3448. Y. Kuroiwa et al., “Manipulation of human minichromosomes to carry (21) Appl. No.: 12/900,165 greater than megabase-sized chromosome inserts.” Nature Biotechnology, 2000, vol. 18, No. 10, pp. 1086-1090. (22) Filed: Oct. 7, 2010 Y. Kuroiwa et al., “Cloned transchromosomic calves producing human immunoglobin.” Nature Biotechnology, 2002, vol. 20, No. 9. (65) Prior Publication Data pp. 889-894. W. Mills et al., “Generation of an approximately 2.4 Mb human X US 2012/OO93785 A1 Apr. 19, 2012 centromere-based minichromosome by targeted telomere-associated chromosome fragmentation in DT40” Human Molecular Genetics, Related U.S. Application Data 1999, vol. 8, No. 5, pp. 751-761. Z. Larin et al., “Advances in human artificial chromosome technol (62) Division of application No. 10/530.207, filed as ogy.” Trends. Genet., 2002, vol. 18, No. 6, pp. 313-319. application No. PCT/JP03/12734 on Oct. 3, 2003, now M. Ikeno et al., “Generation of human artificial chromosomes abandoned. expressing naturally controlled guanosine triphosphate cyclohydrolase I gene.” Genes Cells, 2002, vol. 7, No. 10, pp. 1021 (30) Foreign Application Priority Data 1032. BR. Grimes et al., “Alpha-satellite DNA and vector composition influence rates of human artificial chromosome formation.” Mol. Oct. 4, 2002 (JP) ................................. 2002-292853 Ther. 2002, vol. 5, No. 6, pp. 798-805. H. Masumuto et al., “Centromere Kinetochore no Kino Kozo Hito (51) Int. Cl. Jinko Senshokutai o Mochita Kino Kaiseki.” Protein, Nucleic Acid A6 IK 4.8/00 (2006.01) and Enzyme, 1999, vol. 44, No. 12, pp. 1665-1673. C7H 2L/00 (2006.01) K. Tomizuka et al., “Double trans-chomosomic mice: maintenance of CI2N 15/85 (2006.01) two individual human chromosome fragments containing Ig heavy and kappaloci and expression of fully human antibodies.” Proc. Natl. (52) U.S. Cl. Acad. Sci. USA, 2000, vol. 97. No. 2, pp. 722-727 USPC .......................... 435/320.1; 514/44; 536/23.1 JW. Yang et al. “Human mini-chromosomes with minimal (58) Field of Classification Search centromeres.” Hum. Mol. Genet. 2000, vol.9, No. 12, pp. 1891-1902. USPC .......................... 435/320.1; 514/44; 536/23.1 JM. Robl et al., “Artificial chromosome vectors and expression of See application file for complete search history. complex proteins in transgenic animals.” Theriogenology, 2003, vol. 59, No. 1, pp. 107-113. R. Saffery et al., “Strategies for engineering human chromosomes (56) References Cited with theraputic potential.” The Journal of Gene Medicine, 2002, vol. 4, pp. 5-13. U.S. PATENT DOCUMENTS M. Katoh et al., “Construction of a novel human artificial chromo some vector for gene delivery,” Biochemical and Biophysical 5,942.435 A 8, 1999 Wheeler Research Communications, 2004, vol. 321, pp. 280-290. International Search Reportdated Jan. 20, 2004 for counterpart appli FOREIGN PATENT DOCUMENTS cation PCT/JP0312734 to parent U.S. Appl. No. 10/530.207. EP 1106061 A1 6, 2001 (Continued) WO 02/070648 A2 9, 2002 Primary Examiner — Kevin Hill OTHER PUBLICATIONS (74) Attorney, Agent, or Firm — Sughrue Mion, PLLC Korean Office Action dated Oct. 18, 2010, as issued in Korean Patent (57) ABSTRACT Application No. 10-2005-7005701. The present invention relates to a human artificial chromo Kuroiwa, Yoshimi et al., “Manipulation of human minichromosomes some (HAC) vector and a method for producing the same. The to carry greater than megabase-sized chromosome inserts'. Nature present invention further relates to a method for introducing Biotechnology, vol. 18, pp. 1086-1090, Oct. 18, 2000. foreign DNA using a human artificial chromosome vector and Grimes, Brenda R., et al., “Alpha-Satellite DNA and Vector Compo a method for producing a cell which expresses foreign DNA. sition Influence Rates of Human Artificial Chromosome Formation', Furthermore, the present invention relates to a method for Molecular Therapy, vol. 5, No. 6, pp. 798-805, May 2002. producing a protein. T. Shinohara et al. "Stability of transferred human chromosome fragments in cultured cells and in mice.” Chromosome Research, 5 Claims, 22 Drawing Sheets 2000, vol. 8, pp. 713-725. (12 of 22 Drawing Sheet(s) Filed in Color) US 8,703.482 B2 Page 2 (56) References Cited H. Masumoto et al., “Assay of centromere function using a human OTHER PUBLICATIONS artificial chromosome" 1998, Chromosoma vol. 107, pp. 406-416. European Search Report dated Feb. 15, 2006 for counterpart appli- Japanese Office Action issued Sep. 20, 2011 for counterpart Japanese cation PCT/JP0312734 to parent U.S. Appl. No. 10/530,207. application 2009-185530. U.S. Patent Apr. 22, 2014 Sheet 1 of 22 US 8,703.482 B2 targeting vecter K K: Kpn wild-type K K -X-----X---X-1a-------X. Xx 8X -l -ms-- w8XX&&888&SXX Cer probeS&8:8 te 9. Okto-orbi targeted allele K K U.S. Patent Apr. 22, 2014 Sheet 2 of 22 US 8,703.482 B2 2ip13 Drug resistant clones O e Polymorphism and o - name of gene markers or or cro - PRED65 | PRED3 21g2. - D21S265 CBR D21 S268 222.3 D2S259 Chronosome 2 U.S. Patent Apr. 22, 2014 Sheet 3 of 22 US 8,703.482 B2 Fig. 3 es S.e as o Drug resistant clones gig O C. c. 83 r kb 13.6 m. Honologous recombinant allele 9. Ouw wild-type allele U.S. Patent Apr. 22, 2014 Sheet 4 of 22 US 8,703.482 B2 Fig. 4 U.S. Patent Apr. 22, 2014 Sheet 5 of 22 US 8,703,482 B2 targeting vecter A. pCMVbsr loxP 3'-neo B -ana-(-a-ana & wild-type allele." r a' s 0. X " " ' " . 8.5 kb- : Xbal site homogous recombination in DT40 targeted allele A pcMvbsr loxP 3'-neo B U.S. Patent Apr. 22, 2014 Sheet 6 of 22 US 8,703.482 B2 S. Blasticidin resistant DT40 cones 35s& 3 & 8 is R s to kb 8.5 or m wild-type allele 7.6 “r rhomologous recombinant allele proximat region PCR amplification on the site generated by homologous distal recontration region U.S. Patent Apr. 22, 2014 Sheet 7 of 22 US 8,703.482 B2 Fig. 7 U.S. Patent Apr. 22, 2014 Sheet 8 of 22 US 8,703.482 B2 Fig. 8 Plasmid Peay GFP N \ E: EcoRI / BBan Pcy u/ oxP wild-type E. E. oxP 3. 3 mXXXXXX&X-X mid- --&-X-X-X {mb-mid PCMvBsd "... neo Homologous recombination targeted allele , E . B W-WXW-W--WWSWSWWWL-mid-4-(-m) -->{-> --- Pchy Es PolyEGFP Poly neo U.S. Patent Apr. 22, 2014 Sheet 9 of 22 US 8,703.482 B2 U.S. Patent Apr. 22, 2014 Sheet 10 of 22 US 8,703.482 B2 1 2 3 4 56 78 thresk res, U.S. Patent Apr. 22, 2014 Sheet 11 of 22 US 8,703.482 B2 Fig.11 targeting vecter H: find III te --mm- C targeted allele ygro H 5.8k hyg968 --> 5.9 kb - #21 p96705 N N -------- N Nsi I 1.4 kb 2.6 ko 1.9 kb U.S. Patent Apr. 22, 2014 Sheet 12 of 22 US 8,703.482 B2 Fig. 12 Polymorphism and names of gene markers 21g2. 2c22.11 2 a.22. 12 21q22.13 2 (22.2 Chronosome 21 U.S. Patent Apr. 22, 2014 Sheet 13 of 22 US 8,703.482 B2 Fig. 13 as s Hygromycin resistant s s DT40 clones . R ; U.S. Patent Apr. 22, 2014 Sheet 14 of 22 US 8,703.482 B2 Fig. 14 Hygromycin resistant e DAO cores s. g . 5.9 on xx PCR amplification by s Hyggé8/#21 p98705 Digestion of amplified product with Nis U.S. Patent Apr. 22, 2014 Sheet 15 of 22 US 8,703.482 B2 Fig. 15 U.S. Patent Apr. 22, 2014 Sheet 16 of 22 US 8,703,482 B2 U.S. Patent Apr. 22, 2014 Sheet 17 of 22 US 8,703.482 B2 Fig. 17 U.S. Patent Apr. 22, 2014 Sheet 18 of 22 US 8,703.482 B2 Fig. 18 U.S. Patent Apr. 22, 2014 Sheet 19 of 22 US 8,703.482 B2 -- - - - - - -- -------- -- - - - - -- ++++++ | + + + + + + + + + + + -- -- -- -- I -- 6|-61-I -- - - - -- + + + -- -- - - - - - - - - - -- -- - - -- -- - - - - - - - - - - - - - -- U.S.
Load more

Recommended publications
  • OR11H6 (NM 001004480) Human Tagged ORF Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC214860L3 OR11H6 (NM_001004480) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: OR11H6 (NM_001004480) Human Tagged ORF Clone Tag: Myc-DDK Symbol: OR11H6 Vector: pLenti-C-Myc-DDK-P2A-Puro (PS100092) E. coli Selection: Chloramphenicol (34 ug/mL) Cell Selection: Puromycin ORF Nucleotide The ORF insert of this clone is exactly the same as(RC214860). Sequence: Restriction Sites: SgfI-MluI Cloning Scheme: ACCN: NM_001004480 ORF Size: 990 bp This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 OR11H6 (NM_001004480) Human Tagged ORF Clone – RC214860L3 OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. RefSeq: NM_001004480.1, NP_001004480.1 RefSeq Size: 993 bp RefSeq ORF: 993 bp Locus ID: 122748 UniProt ID: Q8NGC7, A0A126GVP4 Protein Families: Transmembrane Protein Pathways: Olfactory transduction MW: 36.6 kDa Gene Summary: Olfactory receptors interact with odorant molecules in the nose, to initiate a neuronal response that triggers the perception of a smell.
    [Show full text]
  • Human Artificial Chromosome (Hac) Vector
    Europäisches Patentamt *EP001559782A1* (19) European Patent Office Office européen des brevets (11) EP 1 559 782 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC (43) Date of publication: (51) Int Cl.7: C12N 15/09, C12N 1/15, 03.08.2005 Bulletin 2005/31 C12N 1/19, C12N 1/21, C12N 5/10, C12P 21/02 (21) Application number: 03751334.8 (86) International application number: (22) Date of filing: 03.10.2003 PCT/JP2003/012734 (87) International publication number: WO 2004/031385 (15.04.2004 Gazette 2004/16) (84) Designated Contracting States: • KATOH, Motonobu, Tottori University AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Yonago-shi, Tottori 683-8503 (JP) HU IE IT LI LU MC NL PT RO SE SI SK TR • TOMIZUKA, Kazuma, Designated Extension States: Kirin Beer Kabushiki Kaisha AL LT LV MK Takashi-shi, Gunma 370-1295 (JP) • KUROIWA, Yoshimi, (30) Priority: 04.10.2002 JP 2002292853 Kirin Beer Kabushiki Kaisha Takasaki-shi, Gunma 370-1295 (JP) (71) Applicant: KIRIN BEER KABUSHIKI KAISHA • KAKEDA, Minoru, Kirin Beer Kabushiki Kaisha Tokyo 104-8288 (JP) Takasaki-shi, Gunma 370-1295 (JP) (72) Inventors: (74) Representative: HOFFMANN - EITLE • OSHIMURA, Mitsuo, Tottori University Patent- und Rechtsanwälte Yonago-shi, Tottori 683-8503 (JP) Arabellastrasse 4 81925 München (DE) (54) HUMAN ARTIFICIAL CHROMOSOME (HAC) VECTOR (57) The present invention relates to a human arti- ing a cell which expresses foreign DNA. Furthermore, ficial chromosome (HAC) vector and a method for pro- the present invention relates to a method for producing ducing the same.
    [Show full text]
  • Supplementary Methods
    Heterogeneous Contribution of Microdeletions in the Development of Common Generalized and Focal epilepsies. SUPPLEMENTARY METHODS Epilepsy subtype extended description. Genetic Gereralized Epilepsy (GGE): Features unprovoked tonic and/or clonic seizures, originated inconsistently at some focal point within the brain that rapidly generalizes engaging bilateral distributed spikes and waves discharges on the electroencephalogram. This generalization can include cortical and sub cortical structures but not necessarily the entire cortex[1]. GGE is the most common group of epilepsies accounting for 20% of all cases[2]. It is characterized by an age-related onset and a strong familial aggregation and heritability which allows the assumption of a genetic cause. Although genetic associations have been identified, a broad spectrum of causes is acknowledged and remains largely unsolved [3]. Rolandic Epilepsy (RE): Commonly known also as Benign Epilepsy with Centrotemporal Spikes (BECTS), hallmarks early onset diagnosis (mean onset = 7 years old) with brief, focal hemifacial or oropharyngeal sensorimotor seizures alongside speech arrest and secondarily generalized tonic– clonic seizures, which mainly occur during sleep[4]. Rolandic epilepsy features a broad spectrum of less benign related syndromes called atypical Rolandic epilepsy (ARE), including benign partial epilepsy (ABPE), Landau–Kleffner syndrome(LKS) and epileptic encephalopathy with continuous spike-and-waves during sleep (CSWSS)[5]. Together they are the most common childhood epilepsy with a prevalence of 0.2–0.73/1000 (i.e. _1/2500)[6]. Adult Focal Epilepsy (AFE). Focal epilepsy is characterized by sporadic events of seizures originated within a specific brain region and restricted to one hemisphere. Although they can exhibit more than one network of wave discharges on the electroencephalogram, and different degrees of spreading, they feature a consistent site of origin.
    [Show full text]
  • Olfactory Signaling Components and Olfactory Receptors Are Expressed in Tubule Cells of the Human Kidney
    Archives of Biochemistry and Biophysics 610 (2016) 8e15 Contents lists available at ScienceDirect Archives of Biochemistry and Biophysics journal homepage: www.elsevier.com/locate/yabbi Olfactory signaling components and olfactory receptors are expressed in tubule cells of the human kidney * Benjamin Kalbe a, , Marian Schlimm a, Sebastian Wojcik a, Stathis Philippou b, Desir ee Maßberg a, Fabian Jansen a, Paul Scholz a, Hermann Luebbert c, Burkhard Ubrig d, Sabrina Osterloh a, Hanns Hatt a a Department of Cell Physiology, Ruhr-University Bochum, Bochum, Germany b Department of Pathology and Cytology, Augusta-Kranken-Anstalt, Bochum, Germany c Department of Animal Physiology, Ruhr-University Bochum, Bochum, Germany d Clinic for Urology, Augusta-Kranken-Anstalt, Bochum, Germany article info abstract Article history: Cells of the renal tubule system are in direct contact with compounds dissolved in the urine, such as Received 12 August 2016 short chain fatty acids (SCFA). Murine OR78, a member of the olfactory receptor (OR) family, is involved Received in revised form in SCFA-related regulation of renal blood pressure in mice. It is still unclear whether OR signaling has an 26 September 2016 impact on human renal physiology. In our study, we showed that OR51E1 and OR11H7, both of which can Accepted 28 September 2016 be activated by the SCFA isovaleric acid, are expressed in the HK-2 human proximal tubule cell line. We Available online 28 September 2016 þ observed a transient increase in intracellular Ca2 when isovaleric acid and 4-methylvaleric acid were þ added to HK-2 cells. The isovaleric acid-induced response was dependent on extracellular Ca2 and Keywords: adenylyl cyclase (AC) activation.
    [Show full text]
  • Arxiv:1803.09721V1 [Q-Bio.QM] 26 Mar 2018 Profiles from Cancer Cell Lines
    Efficient algorithms to discover alterations with complementary functional association in cancer Rebecca Sarto Basso1, Dorit S. Hochbaum1, Fabio Vandin2,3,4* 1 Department of Industrial Engineering and Operations Research, University of California at Berkeley, CA, USA. 2 Department of Information Engineering, University of Padova, Padova, Italy. 3 Department of Computer Science, Brown University, Providence, RI, USA. 4 Department of Mathematics and Computer Science, University of Southern Denmark, Odense, Denmark. * Corresponding author: [email protected] Abstract Recent large cancer studies have measured somatic alterations in an unprecedented number of tumours. These large datasets allow the identification of cancer-related sets of genetic alterations by identifying relevant combinatorial patterns. Among such patterns, mutual exclusivity has been employed by several recent methods that have shown its effectivenes in characterizing gene sets associated to cancer. Mutual exclusivity arises because of the complementarity, at the functional level, of alterations in genes which are part of a group (e.g., a pathway) performing a given function. The availability of quantitative target profiles, from genetic perturbations or from clinical phenotypes, provides additional information that can be leveraged to improve the identification of cancer related gene sets by discovering groups with complementary functional associations with such targets. In this work we study the problem of finding groups of mutually exclusive alterations associated with a quantitative (functional) target. We propose a combinatorial formulation for the problem, and prove that the associated computation problem is computationally hard. We design two algorithms to solve the problem and implement them in our tool UNCOVER. We provide analytic evidence of the effectiveness of UNCOVER in finding high-quality solutions and show experimentally that UNCOVER finds sets of alterations significantly associated with functional targets in a variety of scenarios.
    [Show full text]
  • Sean Raspet – Molecules
    1. Commercial name: Fructaplex© IUPAC Name: 2-(3,3-dimethylcyclohexyl)-2,5,5-trimethyl-1,3-dioxane SMILES: CC1(C)CCCC(C1)C2(C)OCC(C)(C)CO2 Molecular weight: 240.39 g/mol Volume (cubic Angstroems): 258.88 Atoms number (non-hydrogen): 17 miLogP: 4.43 Structure: Biological Properties: Predicted Druglikenessi: GPCR ligand -0.23 Ion channel modulator -0.03 Kinase inhibitor -0.6 Nuclear receptor ligand 0.15 Protease inhibitor -0.28 Enzyme inhibitor 0.15 Commercial name: Fructaplex© IUPAC Name: 2-(3,3-dimethylcyclohexyl)-2,5,5-trimethyl-1,3-dioxane SMILES: CC1(C)CCCC(C1)C2(C)OCC(C)(C)CO2 Predicted Olfactory Receptor Activityii: OR2L13 83.715% OR1G1 82.761% OR10J5 80.569% OR2W1 78.180% OR7A2 77.696% 2. Commercial name: Sylvoxime© IUPAC Name: N-[4-(1-ethoxyethenyl)-3,3,5,5tetramethylcyclohexylidene]hydroxylamine SMILES: CCOC(=C)C1C(C)(C)CC(CC1(C)C)=NO Molecular weight: 239.36 Volume (cubic Angstroems): 252.83 Atoms number (non-hydrogen): 17 miLogP: 4.33 Structure: Biological Properties: Predicted Druglikeness: GPCR ligand -0.6 Ion channel modulator -0.41 Kinase inhibitor -0.93 Nuclear receptor ligand -0.17 Protease inhibitor -0.39 Enzyme inhibitor 0.01 Commercial name: Sylvoxime© IUPAC Name: N-[4-(1-ethoxyethenyl)-3,3,5,5tetramethylcyclohexylidene]hydroxylamine SMILES: CCOC(=C)C1C(C)(C)CC(CC1(C)C)=NO Predicted Olfactory Receptor Activity: OR52D1 71.900% OR1G1 70.394% 0R52I2 70.392% OR52I1 70.390% OR2Y1 70.378% 3. Commercial name: Hyperflor© IUPAC Name: 2-benzyl-1,3-dioxan-5-one SMILES: O=C1COC(CC2=CC=CC=C2)OC1 Molecular weight: 192.21 g/mol Volume
    [Show full text]
  • Chr CNV Start CNV Stop Gene Gene Feature 1 37261312 37269719
    chr CNV start CNV stop Gene Gene feature 1 37261312 37269719 Tmem131 closest upstream gene 1 37261312 37269719 Cnga3 closest downstream gene 1 41160869 41180390 Tmem182 closest upstream gene 1 41160869 41180390 2610017I09Rik closest downstream gene 1 66835123 66839616 1110028C15Rik in region 2 88714200 88719211 Olfr1206 closest upstream gene 2 88714200 88719211 Olfr1208 closest downstream gene 2 154840037 154846228 a in region 3 30065831 30417157 Mecom closest upstream gene 3 30065831 30417157 Arpm1 closest downstream gene 3 35476875 35495913 Sox2ot closest upstream gene 3 35476875 35495913 Atp11b closest downstream gene 3 39563408 39598697 Fat4 closest upstream gene 3 39563408 39598697 Intu closest downstream gene 3 94246481 94410611 Celf3 in region 3 94246481 94410611 Mrpl9 in region 3 94246481 94410611 Riiad1 in region 3 94246481 94410611 Snx27 in region 3 104311901 104319916 Lrig2 in region 3 144613709 144619149 Clca6 in region 3 144613709 144619149 Clca6 in region 4 108673 137301 Vmn1r2 closest downstream gene 4 3353037 5882883 6330407A03Rik in region 4 3353037 5882883 Chchd7 in region 4 3353037 5882883 Fam110b in region 4 3353037 5882883 Impad1 in region 4 3353037 5882883 Lyn in region 4 3353037 5882883 Mos in region 4 3353037 5882883 Penk in region 4 3353037 5882883 Plag1 in region 4 3353037 5882883 Rps20 in region 4 3353037 5882883 Sdr16c5 in region 4 3353037 5882883 Sdr16c6 in region 4 3353037 5882883 Tgs1 in region 4 3353037 5882883 Tmem68 in region 4 5919294 6304249 Cyp7a1 in region 4 5919294 6304249 Sdcbp in region 4 5919294
    [Show full text]
  • A Study of the Differential Expression Profiles of Keshan Disease Lncrna/Mrna Genes Based on RNA-Seq
    421 Original Article A study of the differential expression profiles of Keshan disease lncRNA/mRNA genes based on RNA-seq Guangyong Huang1, Jingwen Liu2, Yuehai Wang1, Youzhang Xiang3 1Department of Cardiology, Liaocheng People’s Hospital of Shandong University, Liaocheng, China; 2School of Nursing, Liaocheng Vocational & Technical College, Liaocheng, China; 3Shandong Institute for Endemic Disease Control, Jinan, China Contributions: (I) Conception and design: G Huang, Y Xiang; (II) Administrative support: G Huang, Y Wang; (III) Provision of study materials or patients: G Huang, J Liu, Y Xiang; (IV) Collection and assembly of data: G Huang, J Liu; (V) Data analysis and interpretation: J Liu, Y Wang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Guangyong Huang, MD, PhD. Department of Cardiology, Liaocheng People’s Hospital of Shandong University, No. 67 of Dongchang Street, Liaocheng 252000, China. Email: [email protected]. Background: This study aims to analyze the differential expression profiles of lncRNA in Keshan disease (KSD) and to explore the molecular mechanism of the disease occurrence and development. Methods: RNA-seq technology was used to construct the lncRNA/mRNA expression library of a KSD group (n=10) and a control group (n=10), and then Cuffdiff software was used to obtain the gene lncRNA/ mRNA FPKM value as the expression profile of lncRNA/mRNA. The fold changes between the two sets of samples were calculated to obtain differential lncRNA/mRNA expression profiles, and a bioinformatics analysis of differentially expressed genes was performed. Results: A total of 89,905 lncRNAs and 20,315 mRNAs were detected.
    [Show full text]
  • The Hypothalamus As a Hub for SARS-Cov-2 Brain Infection and Pathogenesis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.08.139329; this version posted June 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. The hypothalamus as a hub for SARS-CoV-2 brain infection and pathogenesis Sreekala Nampoothiri1,2#, Florent Sauve1,2#, Gaëtan Ternier1,2ƒ, Daniela Fernandois1,2 ƒ, Caio Coelho1,2, Monica ImBernon1,2, Eleonora Deligia1,2, Romain PerBet1, Vincent Florent1,2,3, Marc Baroncini1,2, Florence Pasquier1,4, François Trottein5, Claude-Alain Maurage1,2, Virginie Mattot1,2‡, Paolo GiacoBini1,2‡, S. Rasika1,2‡*, Vincent Prevot1,2‡* 1 Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, DistAlz, UMR-S 1172, Lille, France 2 LaBoratorY of Development and PlasticitY of the Neuroendocrine Brain, FHU 1000 daYs for health, EGID, School of Medicine, Lille, France 3 Nutrition, Arras General Hospital, Arras, France 4 Centre mémoire ressources et recherche, CHU Lille, LiCEND, Lille, France 5 Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and ImmunitY of Lille (CIIL), Lille, France. # and ƒ These authors contriButed equallY to this work. ‡ These authors directed this work *Correspondence to: [email protected] and [email protected] Short title: Covid-19: the hypothalamic hypothesis 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.06.08.139329; this version posted June 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Identification of Genetic Heterogeneity in a South Indian Family Affected By
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.306191; this version posted October 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Identification of genetic heterogeneity in a South Indian family affected by primary open angle glaucoma. Mohd Hussain Shah1*, Manojkumar Kumaran2,5*, Prakash Chermakani1,6 Mohideen Abdul Kader3, R. Ramakrishnan3, Subbiah. R. Krishnadas4, Bharanidharan Devarajan2@, and Periasamy Sundaresan1@ 1Department of Genetics, Aravind Medical Research Foundation, Madurai, Tamil Nadu, India 2Department of Bioinformatics, Aravind Medical Research Foundation, Madurai, Tamil Nadu, India 3Glaucoma Clinic, Aravind Eye Hospital, Tirunelveli, Tamil Nadu, India 4Glaucoma Clinic, Aravind Eye Hospital, Madurai, Tamil Nadu, India 5School of Chemical and Biotechnology, SASTRA (Deemed to be University), Thanjavur, Tamil Nadu, India 6 Department of Molecular Biology, Alagappa University, Karaikudi, Tamil Nadu, India *First two authors contributed equally to this work @Corresponding Authors. @ Corresponding Authors: Bharanidharan, Devarajan E-Mail: [email protected] Telephone: 91-452-4356550 Extn.444 Periasamy, Sundaresan E-Mail: [email protected] Telephone: 91-4356550 Extn.423 bioRxiv preprint doi: https://doi.org/10.1101/2020.09.21.306191; this version posted October 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Primary open angle glaucoma (POAG) is a complex hereditary disorder; larger pedigree analysis of POAG positive family history has led to the discovery of many candidate genes associated with disease pathogenesis. However, only 5-6% of POAG can explain these genetic factors.
    [Show full text]
  • Lupus Nephritis Supp Table 5
    Supplementary Table 5 : Transcripts and DAVID pathways correlating with the expression of CD4 in lupus kidney biopsies Positive correlation Negative correlation Transcripts Pathways Transcripts Pathways Identifier Gene Symbol Correlation coefficient with CD4 Annotation Cluster 1 Enrichment Score: 26.47 Count P_Value Benjamini Identifier Gene Symbol Correlation coefficient with CD4 Annotation Cluster 1 Enrichment Score: 3.16 Count P_Value Benjamini ILMN_1727284 CD4 1 GOTERM_BP_FAT translational elongation 74 2.50E-42 1.00E-38 ILMN_1681389 C2H2 zinc finger protein-0.40001984 INTERPRO Ubiquitin-conjugating enzyme/RWD-like 17 2.00E-05 4.20E-02 ILMN_1772218 HLA-DPA1 0.934229063 SP_PIR_KEYWORDS ribosome 60 2.00E-41 4.60E-39 ILMN_1768954 RIBC1 -0.400186083 SMART UBCc 14 1.00E-04 3.50E-02 ILMN_1778977 TYROBP 0.933302249 KEGG_PATHWAY Ribosome 65 3.80E-35 6.60E-33 ILMN_1699190 SORCS1 -0.400223681 SP_PIR_KEYWORDS ubl conjugation pathway 81 1.30E-04 2.30E-02 ILMN_1689655 HLA-DRA 0.915891173 SP_PIR_KEYWORDS protein biosynthesis 91 4.10E-34 7.20E-32 ILMN_3249088 LOC93432 -0.400285215 GOTERM_MF_FAT small conjugating protein ligase activity 35 1.40E-04 4.40E-02 ILMN_3228688 HLA-DRB1 0.906190291 SP_PIR_KEYWORDS ribonucleoprotein 114 4.80E-34 6.70E-32 ILMN_1680436 CSH2 -0.400299744 SP_PIR_KEYWORDS ligase 54 1.50E-04 2.00E-02 ILMN_2157441 HLA-DRA 0.902996561 GOTERM_CC_FAT cytosolic ribosome 59 3.20E-33 2.30E-30 ILMN_1722755 KRTAP6-2 -0.400334007 GOTERM_MF_FAT acid-amino acid ligase activity 40 1.60E-04 4.00E-02 ILMN_2066066 HLA-DRB6 0.901531942 SP_PIR_KEYWORDS
    [Show full text]
  • Genetic Variants Affecting Equivalent Protein Family Positions Reflect
    www.nature.com/scientificreports OPEN Genetic variants afecting equivalent protein family positions refect human diversity Received: 13 January 2017 Francesco Raimondi1,2, Matthew J. Betts1,2, Qianhao Lu1,2, Asuka Inoue3,4, J. Silvio Gutkind5 & Accepted: 13 September 2017 Robert B. Russell 1,2 Published: xx xx xxxx Members of diverse protein families often perform overlapping or redundant functions meaning that diferent variations within them could refect diferences between individual organisms. We investigated likely functional positions within aligned protein families that contained a signifcant enrichment of nonsynonymous variants in genomes of healthy individuals. We identifed more than a thousand enriched positions across hundreds of family alignments with roles indicative of mammalian individuality, including sensory perception and the immune system. The most signifcant position is the Arginine from the Olfactory receptor “DRY” motif, which has more variants in healthy individuals than all other positions in the proteome. Odorant binding data suggests that these variants lead to receptor inactivity, and they are mostly mutually exclusive with other loss-of-function (stop/frameshift) variants. Some DRY Arginine variants correlate with smell preferences in sub-populations and all 2,504 humans studied contain a unique spectrum of active and inactive receptors. The many other variant enriched positions, across hundreds of other families might also provide insights into individual diferences. Genomes from healthy individuals1 illuminate both diseases2 and attributes of individuals or human popula- tions3,4. Perhaps the most common current use of these genomes is to provide background mutation rates to assess candidate disease mutations or to identify likely deleterious genetic alterations5,6. For example, ExAC6 is frequently used by human geneticists to determine variant frequency during searches for disease causing mutations.
    [Show full text]